MerLion Pharmaceuticals Pte Ltd Company Profile
MerLion Pharmaceuticals is a Singapore-based, privately held company, engaged in drug discovery from natural products. Its assets include one of the World's largest and most diverse natural product collections, proprietary purification technologies, high throughput screening (HTS) capabilities, proprietary IT database management systems and a highly experienced team. Our business focus is on discrete R & D collaborations with pharmaceutical companies, biotechs and other research organisations possessing novel, validated targets in key therapeutic areas.
MerLion Pharmaceuticals Pte Ltd was formed in 2002 through the privatisation of the former Centre for Natural Product Research (CNPR), a unique unit of Singapore's Institute of Molecular and Cell Biology (IMCB). Funded in part by former-Glaxo and the Economic Development Board of Singapore, CNPR was established in 1993 to screen natural product samples in the search for new pharmaceutical leads. From 1993 to 2002, CNPR established first class lead discovery capabilities, undertaking high throughput screens in a wide range of formats and discovering a vast array of active compounds, many completely new to science. MerLion Pharma has inherited all assets of CNPR, including all key staff, an impressive collection of natural product samples, as well as a portfolio of promising lead compounds in a range of therapeutic areas. MerLion Pharma has since acquired additional natural product libraries and, together with MerLion's legacy libraries, they represent a collection unparalleled in geographic and taxonomic diversity, giving the Company a significant competitive edge in this field of drug discovery.
1 Science Park Road #05-01 The Capricorn
Singapore Science Park II
Phone: (65) 6829-5600
Fax: (65) 6829-5601
Early clinical results with an intravenous formulation of MerLion Pharmaceuticals' finafloxacin indicate good potential for the use of the novel fluoroquinolone antibacterial in critical care setting...
Singapore’s MerLion pushes ahead with its finafloxacin anti-bacterial candidate, successfully completing Phase I trials of an intravenous version.
MerLion will enroll as many as 258 patients across centers in Germany and Poland for patients requiring hospitalization for urinary tract infections and pyelonephritis, positive signs for a drug in-li...
Drugs and Medications
Review of Natural Product Chemistry for Drug Discovery Natural Product Chemistry for Drug Discovery . By Anthony D.Buss and Mark S.Butler (MerLion Pharmaceuticals, Singapore). RSC Publishing : Cambridge . 2010 . xviii + 440 pp. 16 × 24 cm. £144.99. ISBN
A 384-well microtitre plate fluorescence cleavage assay was developed to identify inhibitors of the cysteine protease falcipain-2, an important antimalarial drug target. Bioassay-guided isolation of a...
The absolute configuration (via degradation and Marfey's derivatization studies) and the total synthesis of a novel antimalarial lipid-peptide isolated from Streptomyces sp. (IC(50) = 0.8 μM, Plasmod...
MerLion Pharmaceuticals is a Singapore-based, privately held company, engaged in drug discovery from natural products. Its assets include one of the World's largest and most diverse natural product co...
More Information about "MerLion Pharmaceuticals Pte Ltd" on BioPortfolio
We have published hundreds of MerLion Pharmaceuticals Pte Ltd news stories on BioPortfolio along with dozens of MerLion Pharmaceuticals Pte Ltd Clinical Trials and PubMed Articles about MerLion Pharmaceuticals Pte Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MerLion Pharmaceuticals Pte Ltd Companies in our database. You can also find out about relevant MerLion Pharmaceuticals Pte Ltd Drugs and Medications on this site too.